ClinicalTrials.gg
CompletedNCT05814809Updated Apr 20, 2023

Clinical Trial to Evaluate the Safety and Pharmacokinetics of JP-1366 in Healthy Adult Volunteers

A Phase 1 interventional study of JP-1366 20mg tablet and JP-1366 20mg capsule in Healthy, sponsored by Onconic Therapeutics Inc.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-20.

Sponsored by Onconic Therapeutics Inc. (part of Jeil Pharmaceutical Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Sep 2022, registered Apr 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

To evaluate the safety and the pharmacokinetics of the JP-1366 20 mg tablet and capsule oral administration in healthy adult volunteers.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Onconic Therapeutics Inc. is the lead sponsor of 19 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects ≥ 19 years of age
  2. Subjects who weigh ≥ 50 kg (or ≥ 45 kg in the case of females) with (BMI) of ≥ 18.0 kg/m2 and ≤ 30.0 kg/m2

Exclusion criteria

Exclusion Criteria:

  1. Subjects with diseases or a medical history related to the digestive system, cardiovascular system, endocrine system, respiratory system, blood and tumor, infections diseases, kidney and urinary system, psychiatric and nervous system, musculoskeletal system, immune system, otorhinolaryngology, skin, and ophthalmological system
  2. Subjects who have a history of gastrointestinal surgery (except simple appendectomy or herniotomy) or have gastrointestinal disorders that may affect the absorption of the drug
  3. Subjects who received inducers or inhibitors of drug metabolizing enzymes
  4. Subjects who have to this drug, ingredients of this drug, or benzimidazoles, or have a medical history thereof
  5. Patients receiving drugs containing atazanavir, nelfinavir, or rilpivirine
  6. Subjects who are judged ineligible to participate in this study by the principal investigator
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Sequence A

    R → Washout period(7days) → T

    Drug: JP-1366 20mg tablet · Drug: JP-1366 20mg capsule

  • Experimental
    Sequence B

    T → Washout period(7days) → R

    Drug: JP-1366 20mg tablet · Drug: JP-1366 20mg capsule

Interventions

06

What researchers measure

Primary outcomes

  1. AUCt of Zastaprazan(JP-1366 20mg)

    Time frame: Pre-dose(0 hour) and up to 34 hours in each period

  2. Cmax of Zastaprazan(JP-1366 20mg)

    Time frame: Pre-dose(0 hour) and up to 34 hours in each period

07

Study locations

1 site
  • Yangji Hospital
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2022 to primary completion in Oct 2022, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2023
First posted
Apr 18, 2023
StartActual
Sep 30, 2022
Primary completionActual
Oct 9, 2022
CompletionActual
Nov 9, 2022
Last update
Apr 20, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05814809
Responsible party
Sponsor
First posted
Apr 18, 2023
Start date
Sep 30, 2022
Primary completion
Oct 9, 2022
Completion
Nov 9, 2022
Last update
Apr 20, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zastaprazan

Start the discussion